Clinical Trial: Phase 3 Trial of SRG-514 Administered Intraoperatively to Patients Undergoing Breast-Conserving Surgery

U.S., July 24 -- ClinicalTrials.gov registry received information related to the study (NCT07723469) titled 'Phase 3 Trial of SRG-514 Administered Intraoperatively to Patients Undergoing Breast-Conserving Surgery' on July 20.

Brief Summary: This is a Phase 3 trial to compare SRG-514 (active pharmaceutical ingredient [API]: ketorolac) administered intraoperatively to the tumor resection cavity with standard-of-care (SOC) versus SOC alone in participants with clinical stage II-III triple negative breast cancer (TNBC) undergoing breast-conserving surgery (BCS) who are neoadjuvant therapy naive.

Study Start Date: Oct., 2026

Study Type: INTERVENTIONAL

Condition: TNBC - Triple-Negative Breast Cancer

Intervention: DRUG: BCS + SRG-514

BCS +...